Directory of services
| DIRECTORY OF SERVICES | |||||
| Area of analysis: Evaluation of medical devices | |||||
| Mode of analysis: hemocompatibility tests | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Evaluation of hemocompatibility of dialyzers, oxygenators, plasma filters and other medical devices according to DIN EN ISO 10993-4:2017 (sC5b-9, C3a, TAT, Cell count, Heparin, Hemolysis, NIH and others) | Medical devices, biomaterials | Ex vivo recirculation with heparinized human blood | AA-001, 17/02.2025 | Ismatec MCP, Ismatec MCP-Process | + |
| Evaluation of hemocompatibility of flat sheet membranes and medical devices according to DIN EN ISO 10993-4:2017 in petri-dish-model | Medical devices, Flat sheets, Flat sheet membranes, Particles, biomaterials | Ex vivo incubation with heparinized human blood | AA-010, 10/02.2025 | Certomat U | + |
| MAT – Monocyte activation test according to Ph. Eur. 2.6.30, Quantitative detection of pyrogens in human whole blood model by IL-1ß | Medical devices, biomaterials | Incubation with heparinized human blood | AA-012, 20/02.2025 AA-096, 02/02.2025 |
Certomat U | + |
| Pyrogenretention (ex vivo) | Hemodialyzers, medical devices with hollow fiber membranes | Ex vivo Hemodialysis, Cytokine induction | AA-011, 05/05.2011 | Ismatec MCP, Ismatec MCP-Process | – |
| Released: | |||||
| Date: | |||||
| Area of analysis: Microbiological-hygienic testing of medical devices | |||||
| Mode of analysis: Quantitive determination of pyrogenic contaminants | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Determination of endotoxins/pyrogens by LAL-Assay accoring to Ph. Eur. 2.6.14 | Medical products, raw materials | Turbidimetry | AA-013, 05/02.2025 | BioTek ELx808 | + |
| Area of analysis: Evaluation of medical devices | |||||
| Mode of analysis: Quality testing | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Evaluation of redness | Hemodialyzer, medical devices with hollow fiber membranes | 1) Recirculation model with heparinized human blood; Image analysis 2) Clinical testing; Image analysis |
AA-067, 03/12.2017 | Minolta Chroma-Meter CR-310 | – |
| Particle count | Hemodialyzer, medical devices, tubing sets | Particel count in rinsing solution | AA-079, 03/03.2017 | Ismatec MCP | – |
| Gravity driven plasmaseparation | Loop module | Plasmaseparation | AA-087, 03/06.2016 | Test Rig, Plasmafilter | – |
| Structural integrity according to DIN EN ISO 8637-1:2020 | Hemodialyzers, hemodiafilter, hemofilter, hemoconcentrators | Pressure hold test | AA-094, 03/06.2025 | Pressure hold equipment, vacuum pump | + |
| Integrity test of the blood compartment according to DIN EN ISO 8637-1:2020 | Hemodialyzers, hemodiafilter, hemofilter, hemoconcentrators | Pressure hold test of the blood compartment | AA-104, 01/07.2023 | Pressure hold equipment, dialysis monitor | + |
| Structural integrity test/Leak test and integrity of the blood compartment of plasmafilters according to ISO 8637-3 | Plasmafilters | Pressure hold test | AA-091, 05/06.2025 | Pressure hold equipment, vacuum pump | – |
| Area of analysis: Evaluation of medical devices | |||||
| Mode of analysis: Determination of performance parameters | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Low molecular weight solute clearance according to DIN EN ISO 8637-1:2020 (ex vivo) | Hemodialyzers, hemodiafilter, hemofilter, hemoconcentrators | Ex vivo Hemodialysis | AA-039, 19/04.2024 | Dialysis monitor | + |
| Blood clearance of middle molecules with albumin loss according to DIN EN ISO 8637-1:2020 | Hemodialyzers, hemodiafilter, hemofilter, hemoconcentrators | Ex vivo Hemodialysis | AA-039, 19/04.2024 | Dialysis monitor | + |
| Clearance according to japanese standard: Manual for Functional Classification of Dialyzers; Methods for performance evaluation of blood purifiers | Hemodialyzers, hemodiafilter, hemofilter, hemoconcentrators | Ex vivo Hemodialysis | AA-100, 01/05.2020 | Dialysis monitor | + |
| Determination of sieving coefficients according to DIN EN ISO 8637-1:2020 (ex vivo) | Hemodialyzers, hemodiafilter, hemofilter, hemoconcentrators | Ex vivo Hemodialysis | AA-040, 11/04.2024 | Dialysis monitor | + |
| Determination of pressure drop, Volume of blood compartment, transmembrane pressure TMP, ultrafiltration rate UFR and ultrafiltration coefficient KUF according to DIN EN ISO 8637-1:2020 | Hemodialyzers, hemodiafilter, hemofilter, hemoconcentrators | Hemodialysis; Recirculation model with heparinized human blood | AA-065, 10/04.2024 AA-042, 03/05.2013 |
Dialysis monitor | + |
| Determination of performance parameters of plasmafilters (Sieving coefficients, filtration rate, hemolysis, TMP) according to ISO 8637-3 | Plasmafilter | ex vivo Recirculation model with heparinized human blood | AA-091, 06/06.2025 | Dialysis monitor | – |
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Isolation of proteins from hemofiltrate of patients with Kidney Failure (ex vivo) | Hemofiltrate | Ultrafiltration, Chromatography | AA-037, 07/08.2022 | Ismatec MCP, Ismatec MCP-Process | – |
| Determination of performance parameters of plasmafractionation devices (Sieving Coefficients, ex vivo) | Plasmafractionation devices | ex vivo Plasmafractionation | AA-077, 05/03.2016 | Plasmafractionation monitor Infomed CF-100 | – |
| Determination of O2 and CO2 transfer rates of oxygenators according to DIN EN ISO 7199:2020 | Oxygenators | ex vivo Recirculation model with heparinized human blood | AA-102, 01/02.2022 | Customer specified blood pump | + |
| Retention and damage of blood cells/plasma components by transfusion sets according to DIN EN ISO 1135-4:2016 and 1135-5:2016 | Transfusion sets, pumps for transfusion | Filtration of different media (blood/plasma products) through the transfusion sets | AA-105, 01/01.2024 | Transfusion sets, pumps for transfusion | + |
| Blood Cell Damage (BCD) according to DIN EN ISO 7199 | Oxygenators | ex vivo Recirculation model with heparinized human blood | AA-106, 01/06.2025 | Customer specified blood pump | – |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Spectrometry (UV-/ VIS-Photometry/ Nephelometry) | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| a-Amylase | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| α1-Antitrypsin | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| α1-acidic Glycoprotein | Heparinized plasma, Serum, Aqueous Solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| α1-Microglobulin | Heparinized plasma, Serum, Urine, Aqueous Solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| α2-Macroglobulin | Heparinized plasma, Serum, Urine, Aqueous Solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| ADNase B | Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Alanine aminotransferase | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Albumin | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Albumin | Citrated plasma, Serum, Aqueous Solutions* | Photometry (BCG method) | AA-103, 01/10.2022 | BioTek ELx808 | + |
| Albumin | Heparinized and EDTA plasma, Serum, Urine, Aqueous Solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| * aqueous solution: in house validated; out of scope of D-PL-19275-01-00, within the scope of D-PL-19275-02-00 | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Alkaline phosphatase | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Ammonia | EDTA plasma | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Antistreptolysin (ASL) | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Antithrombin III | EDTA and citrated plasma | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Apolipoprotein A-I | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Apolipoprotein A-II | Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Apolipoprotein B | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Apolipoprotein E | Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Aspartate aminotransferase | Heparinized and EDTA plasma | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| ß2-Microglobulin | Heparinized plasma, Serum, Urine, Aqueous Solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| BCA, Protein determination | Heparinized, citrated and EDTA plasma, Serum, Aqueous Solutions* | Photometry | AA-074, 06/02.2025 | BioTek ELx808 | + |
| Bicarbonate | Heparinized plasma | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Bilirubin Direct | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| * aqueous solution: in house validated; out of scope of D-PL-19275-01-00, within the scope of D-PL-19275-02-00 | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Bilirubin Total | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| C1-Inhibitor | EDTA and citrated plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Calcium | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Carbohydrate-Deficient Transferrin | Haparinzed and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Cholesterol | Haparinzed and EDTA plasma, Serum, Aqueous solutions* | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Coeruloplasmin | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| C-reactive Protein (CRP) | Haparinzed and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| C-reactive Protein (CRP) | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| C-reactive Protein (CRP) High Sensitive | Haparinzed and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Creatinine | Haparinzed and EDTA plasma, Serum, Urine, Aqueous solutions* | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Creatinine (Jaffé) | Haparinzed and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Creatine kinase | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Cystatin C | Heparinized and EDTA plasma, Serum, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| * aqueous solution: in house validated; out of scope of D-PL-19275-01-00, within the scope of D-PL-19275-02-00 | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| DEHP equivalents | Aqueous solutions | Photometry | AA-099, 01/07.2019 | Shimadzu UV-1650PC | – |
| D-Dimer | Heparinized, EDTA and Citrated plasma | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Ferrum | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Factor VIII Coatest | Citrated plasma | Photometrie | AA-093, 02/07.2019 | BioTek ELx808 | + |
| Ferritin | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Fibrinogen | EDTA and citrated plasma, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| Fibronectin | EDTA and citrated plasma | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| free Hemoglobin in plasma (hemolysis) | Heparinized plasma, Serum | Photometry | AA-056, 13/02.2025 | Shimadzu UV-1650PC | + |
| Glucose | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Hemopexin | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Haptoglobin | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| HbA1c | Heparinized and EDTA plasma | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| HDL Cholesterol | Heparinized and EDTA plasma, Serum, Aqueous solutions* | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| * aqueous solution: in house validated; out of scope of D-PL-19275-01-00, within the scope of D-PL-19275-02-00 | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Heparin | Citrated plasma | Photometry | AA-002, 16/06.2025 | BioTek ELx808 | + |
| Homocysteine | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Free Immunoglubulin Light chains, Type kappa | Heparinized and EDTA plasma, Serum, Urine, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| Free Immunoglubulin Light chains, Type lambda | Heparinized and EDTA plasma, Serum, Urine, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| Immunoglobulin A (IgA) | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Immunoglobulin E (IgE) | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Immunoglobulin G (IgG) | Heparinized plasma, Serum, Urine, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| Immunoglobulin G (IgG) Subclass 1 | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Immunoglobulin G (IgG) subclass 2 | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Immunoglobulin G (IgG) subclass 3 | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Immunoglobulin G (IgG) subclass 4 | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Immunoglobulin M (IgM) | Heparinized plasma, Serum, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| Inulin | CPD, Citrated and Heparinized plasma, Aqueous solutions* | Photometry | AA-048, 10/04.2023 | Shimadzu UV-1650PC | + |
| * aqueous solution: in house validated; out of scope of D-PL-19275-01-00, within the scope of D-PL-19275-02-00 | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Iron | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Complement factor C3c | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Complement factor C4 | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Lactate | Heparinized plasma | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| LDH | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| LDL-Cholesterol | Heparinized plasma, Serum, Aqueous solutions* | Photometrie | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Lipase | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Lipoprotein (a) | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Magnesium | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Myoglobin | Heparinized and EDTA plasma, Serum, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| Pancreatic a-Amylase | Heparinized plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Peroxide (PerOX) | EDTA plasma, Serum | Photometry | AA-019, 13/02.2025 | BioTek ELx808 | + |
| Phosphate | Heparinized and EDTA plasma, Serum, Urine, Aqueous solutions* | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Plasminogen | EDTA and citrated plasma | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| * aqueous solution: in house validated; out of scope of D-PL-19275-01-00, within the scope of D-PL-19275-02-00 | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Pre albumin | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Retinol binding Protein (RBP) | Heparinized plasma, Serum, Aqueous solutions* | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | + |
| Rheumatoid factor (RF) | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Serum Amyloid A Protein (SAA) | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Soluble Transferrin Receptor | Heparinized plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Total protein | Heparinized and EDTA plasma, Serum, Urine, Aqueous solutions* | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Transferrin | Heparinized and EDTA plasma, Serum | Nephelometry | AA-014, 12/07.2019 | Siemens BN ProSpec | – |
| Triglyceride | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Urea | Heparinized and EDTA plasma, Serum, Urine, Aqueous solutions* | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | + |
| Uric Acid | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| Vitamin B12 | Heparinized and EDTA plasma, Serum, Aqueous solutions* | Photometry | AA-047, 14/06.2025 | Shimadzu UV-1650PC | + |
| γ‑Glutamyltransferase | Heparinized and EDTA plasma, Serum | Photometry | AA-057, 10/07.2019 | Roche cobas c111 | – |
| * aqueous solution: in house validated; out of scope of D-PL-19275-01-00, within the scope of D-PL-19275-02-00 | |||||
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Flow cytometry | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Apoptose / Annexin V | Heparinized blood | Flow cytometry | AA-020, 05/07.2019 | BD FACSVerse | + |
| Characterisation MSC | Cell culture | Flow cytometry | AA-095, 01/02.2016 | BD FACSVerse | – |
| Oxidative Burst | Heparinized blood | Flow cytometry | AA-021, 14/02.2025 | BD FACSVerse | + |
| Granulocyte Activation | EDTA blood | Flow cytometry | AA-075, 04/02.2025 | BD FACSVerse | + |
| Monocyte Subpopulations | EDTA blood | Flow cytometry | AA-080, 07/03.2017 | BD FACSVerse | + |
| BD Leucocount | Heparinized plasma | Flow cytometry | AA-083, 02/06.2015 | BD FACSVerse | + |
| TBNK-Lymphocyte Subpopulations | EDTA blood | Flow cytometry | AA-084, 02/07.2014 | BD FACSVerse | + |
| BD Plasma Count | Heparinized, Citrated and EDTA plasma | Flow cytometry | AA-085, 07/10.2017 | BD FACSVerse | + |
| Dentritic cells | EDTA blood | Flow cytometry | AA-086, 03/06.2015 | BD FACSVerse | + |
| Platelet activation PAC-1/CD62P | Citrated blood | Flow cytometry | AA-098, 08/02.2025 | BD FACSVerse | + |
| Blood cells: Platelets, Erythrocytes, Leucocytes, Hematocrit, Hemoglobin etc. | Heparinized, Citrated and EDTA blood | Impedance method | AA-005, 13/02.2025 | ABX Pentra 60 C+ | + |
| Cell Viability | Heparinized, Citrated and EDTA plasma, Cell culture | Flow cytometry | AA-092, 03/03.2017 | BD FACSVerse | – |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Ligand assays (ELISA) | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| HMW-Adiponectin | Heparinized and Citrated plasma, Serum | ELISA | Instructions from the supplier | BioTek ELx808 | – |
| Total-Adiponectin | Heparinized and Citrated plasma, Serum | ELISA | Instructions from the supplier | BioTek ELx808 | – |
| Apolipoprotein C3 | Heparinized and EDTA plasma, Serum | ELISA | Instructions from the supplier | BioTek ELx808 | – |
| Bisphenol A (BPA) | Heparinized and Citrated plasma, Serum | ELSIA | AA-030, 05/06.2015 | BioTek ELx808 | + |
| BNP | Plasma, Serum | ELISA | Instructions from the supplier | BioTek ELx808 | – |
| Bradykinin | EDTA plasma | ELISA | AA-017, 07/05.2020 | BioTek ELx808 | + |
| Fetuin A | Serum | ELISA | Instructions from the supplier | BioTek ELx808 | – |
| FGF23 | EDTA plasma, cell culture medium | ELISA | Instructions from the supplier | BioTek ELx808 | – |
| Interleukin 1-ß | Heparinized, Citrated and EDTA plasma, Serum | ELISA | AA-012, 20/02.2025 | BioTek ELx808 | + |
| Interleukin 6 | Heparinized, Citrated and EDTA plasma, Serum | ELISA | AA-038, 09/02.2021 | BioTek ELx808 | + |
| Complementaktivation: C3a, C5a, sC5b-9 | Citrated and EDTA plasma | ELISA | AA-004, 13/02.2025 | BioTek ELx808 | + |
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Leptin | Heparinized, Citrated and EDTA plasma, Serum | ELISA | AA-101, 01/05.2020 | BioTek ELx808 | – |
| Myeloperoxidase (MPO) | EDTA plasma | ELISA | AA-024, 10/02.2025 | BioTek ELx808 | + |
| ox LDL | Heparinized and EDTA plasma, Serum | ELISA | AA-036, 09/02.2025 | BioTek ELx808 | + |
| Platelet factor 4 (PF4) | CTAD plasma | ELISA | AA-015, 16/02.2025 | BioTek ELx808 | + |
| PMN Elastase | Citrated and EDTA plasma | ELISA | AA-022, 08/02.2025 | BioTek ELx808 | + |
| Thrombin-Antithrombin III-Complex (TAT) | Citrated plasma | ELISA | AA-003, 13/02.2025 | BioTek ELx808 | + |
| TNF-α | Heparinized, Citrated and EDTA plasma, Serum | ELISA | AA-029, 05/04.2023 | BioTek ELx808 | + |
| Factor V | Citrated and EDTA plasma | ELISA | AA-069, 06/07.2019 | BioTek ELx808 | + |
| Factor X | Citrated and EDTA plasma | ELISA | AA-070, 04/07.2019 | BioTek ELx808 | + |
| Protein C | Citrated plasma | ELISA | AA-071, 04/06.2015 | BioTek ELx808 | – |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Chromatography | |||||
| High Perfandmance Liquid Chromatography (HPLC) | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Indoxyl sulfate | Heparinized, Citrated and EDTA plasma, Serum | HPLC | AA-060, 09/02.2025 | Dionex Ultimate 3000 | + |
| p-Cresyl sulfate | Heparinized, Citrated and EDTA plasma, Serum | HPLC | AA-060, 09/02.2025 | Dionex Ultimate 3000 | + |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Elektrophoresis | |||||
| Elektrophandese (SDS-Gelektrophoresis) | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Relative molecular weight of proteins | Heparinized, Citrated and EDTA plasma, Serum | SDS-Gel electrophoresis | AA-051, 04/02.2025 | Electrophoresis equipment EPS 301 | + |
| Proteins | Heparinized, Citrated and EDTA plasma, Serum | Gel electrophoresis (IEF / 2-D PAGE) | AA-073, 01/12.2013 | Electrophoresis equipment EPS 301 | + |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Electrochemical measurements | |||||
| Potentiometry | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Na+ | Heparinized blood | Potentiometry | BA-014, 02/01.2024 BA-022, 01/06.2015 | Cobas b 123 OPTI CCA-TS | + |
| K+ | Heparinized blood | Potentiometry | BA-014, 02/01.2024 BA-022, 01/06.2015 | Cobas b 123 OPTI CCA-TS | + |
| Cl- | Heparinized blood | Potentiometry | BA-014, 02/01.2024 BA-022, 01/06.2015 | Cobas b 123 OPTI CCA-TS | + |
| Ca2+ | Heparinized blood | Potentiometry | BA-014, 02/01.2024 BA-022, 01/06.2015 | Cobas b 123 OPTI CCA-TS | + |
| pH | Heparinized blood | Potentiometry | BA-014, 02/01.2024 BA-022, 01/06.2015 | Cobas b 123 OPTI CCA-TS | + |
| PO2 | Heparinized blood | Amperometry | BA-014, 02/01.2024 BA-022, 01/06.2015 | Cobas b 123 OPTI CCA-TS | + |
| PCO2 | Heparinized blood | Potentiometry | BA-014, 02/01.2024 BA-022, 01/06.2015 | Cobas b 123 OPTI CCA-TS | + |
| Glucose | Heparinized blood | Amperometry | BA-014, 02/01.2024 | Cobas b 123 | + |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Fluorescence spektrometry | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Cytotoxicity ex vivo according to DIN EN ISO 10993-5 | Aqueous solutions, Extracts | Fluorimetry | AA-035, 07/07.2019 DIN EN ISO 10993-5, DIN EN ISO 10993-12 |
BioTek ELx808 | – |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Light microscopy | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Blood slides, Microscopic evaluation of blood slides, Erythrocytes | Blood slide | Microscopy | AA-097, 01/06.2016 | RAL Stainbox, HemaPrep, Leitz, Laborlux 12 | – |
| Area of analysis: Biochemistry/Clinical chemistry | |||||
| Mode of analysis: Coagulometry | |||||
| Analyte (measured variable) | Sample material (Matrix) | Method | SOP/Standard | Equipment | Accredited |
| Determination of ACT with GEM Hemochron 100 | Heparinized blood | Coagulometry | AA-108, 01/06.2025 | GEM Hemochron 100 | – |
To ensure that our tests meet the requirements of our customers, we have established a quality system that fulfils all the requirements of DIN EN ISO/IEC 17025:2018 and ensures the implementation of our quality policy. This makes us an accredited testing and research institute in the areas mentioned. Our accreditation is valid in around 46 countries worldwide (including the EU, the USA and Japan), as a mutual recognition agreement, known as the ILAC Arrangement, applies between the laboratory accreditation bodies of these countries.